Case filing & court posture: Omega Therapeutics, Inc. filed chapter 11 on February 10, 2025 in the United States Bankruptcy Court for the District of Delaware (Case No. 25-10211). Dkt. 1 Judge Brendan L. Shannon presides.
Liquidity & financing path: Pioneering Medicines 08-B, Inc. (PM08-B), which held a $1.5 million prepetition secured loan, provided approximately $10.4 million in DIP financing. Dkt. 44 The debtor filed a motion for sale of substantially all assets on February 17, 2025, with PM08-B serving as stalking horse bidder. Dkt. 51 Bidding procedures were approved on March 12, 2025. Dkt. 102
Restructuring outcome: The 363 sale to PM08-B closed on April 25, 2025 for a credit bid of approximately $12.17 million plus $2.5 million cash. The debtor filed a combined disclosure statement and liquidating plan on June 16, 2025. Dkt. 291
Plan effective date & post-confirmation: The plan was confirmed on July 31, 2025. The plan became effective on August 8, 2025, with Steven Balasiano of MHR Advisory Group appointed as plan administrator.
Current status: The case remains open in post-confirmation liquidation with projected recoveries of 32-57% for general unsecured creditors. The plan administrator continues to administer claims and make distributions.